EUCTR2006-006636-22-FI进行中（未招募）不适用
Histamiini H2 salpaus liitännäishoitona puutteellisen hoitovasteen skitsofreniassa
Jesper Ekelund0 个研究点开始时间: 2007年1月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen AortenstenoseHAVAS-Studie(Haemate HS in patients with severe bleeding undergoing valve replacement due to aortic stenosis) - HAVASIntraoperative Blutungsneigung während des Aortenklappenersatzes bei Patienten mit isolierter valvulärer Aortenstenose oder kombiniertem Aortenvitium mit führender StenoseKlassifikationscode ICD10: a) 68.8 Sonstige näher bezeichnetet Koagulopathie, b) 35.0 AortenklappenstenoseMedDRA 9.0 (LLT) a) 10009730 b) 10002918MedDRA version: 9.1Level: LLTClassification code 10009730Term: Coagulation defects, other and unspecifiedMedDRA version: 9.1Level: LLTClassification code 10002918Term: Aortic valve stenosisEUCTR2006-005296-18-DEHeinrich-Heine-Universität Duesseldorf40
进行中（未招募）
1 期
HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with MK 524A (ER niacin and laropipirant). - HPS2-THRIVECardiovascular disease: History of myocardial infarctionor cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation)or peripheral arterial disease (i.e. intermittent claudication or history of revascularisation)or diabetes mellitus with any of the above or with other evidence of symptomatic coronary heart disease.EUCTR2006-001885-17-GBCTSU, University of Oxford25,000
进行中（未招募）
不适用
HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524. - HPS2-THRIVECardiovascular disease: History of myocardial infarctionor cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation)or peripheral arterial disease (i.e. intermittent claudication or history of revascularisation)or diabetes mellitus with any of the above or with other evidence of symptomatic coronary heart disease.MedDRA version: 14.1Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2006-001885-17-DKniversity of Oxford25,000
进行中（未招募）
不适用
HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524. - HPS2-THRIVECardiovascular disease: History of myocardial infarctionor cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation)or peripheral arterial disease (i.e. intermittent claudication or history of revascularisation)or diabetes mellitus with any of the above or with other evidence of symptomatic coronary heart disease.MedDRA version: 9.0Level: LLTClassification code 10051615EUCTR2006-001885-17-SEniversity of Oxford20,000
进行中（未招募）
不适用
HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524. - HPS2-THRIVEEUCTR2006-001885-17-FIniversity of Oxford20,000